JP2016523269A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523269A5 JP2016523269A5 JP2016522232A JP2016522232A JP2016523269A5 JP 2016523269 A5 JP2016523269 A5 JP 2016523269A5 JP 2016522232 A JP2016522232 A JP 2016522232A JP 2016522232 A JP2016522232 A JP 2016522232A JP 2016523269 A5 JP2016523269 A5 JP 2016523269A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocyclyl
- ring
- substituted
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 37
- 125000000623 heterocyclic group Chemical group 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 23
- 229910052736 halogen Inorganic materials 0.000 claims 23
- 150000002367 halogens Chemical class 0.000 claims 23
- 125000001072 heteroaryl group Chemical group 0.000 claims 19
- 125000001424 substituent group Chemical group 0.000 claims 19
- 125000001188 haloalkyl group Chemical group 0.000 claims 16
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 125000000304 alkynyl group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 241000257303 Hymenoptera Species 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- -1 pyridooxazinyl Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 102000009929 raf Kinases Human genes 0.000 claims 2
- 108010077182 raf Kinases Proteins 0.000 claims 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2013/078338 | 2013-06-28 | ||
| CN2013078338 | 2013-06-28 | ||
| PCT/CN2014/080983 WO2014206343A1 (en) | 2013-06-28 | 2014-06-27 | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018135807A Division JP6707584B2 (ja) | 2013-06-28 | 2018-07-19 | Ｒａｆキナーゼおよび／またはＲａｆキナーゼの二量体阻害剤としての縮合三環式ウレア系化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523269A JP2016523269A (ja) | 2016-08-08 |
| JP2016523269A5 true JP2016523269A5 (https=) | 2017-08-10 |
| JP6380861B2 JP6380861B2 (ja) | 2018-08-29 |
Family
ID=52141106
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016522232A Active JP6380861B2 (ja) | 2013-06-28 | 2014-06-27 | Ｒａｆキナ−ゼおよび／またはＲａｆキナ−ゼの二量体阻害剤としての縮合三環式ウレア系化合物 |
| JP2018135807A Active JP6707584B2 (ja) | 2013-06-28 | 2018-07-19 | Ｒａｆキナーゼおよび／またはＲａｆキナーゼの二量体阻害剤としての縮合三環式ウレア系化合物 |
| JP2020088185A Active JP6889311B2 (ja) | 2013-06-28 | 2020-05-20 | Ｒａｆキナーゼおよび／またはＲａｆキナーゼの二量体阻害剤としての縮合三環式ウレア系化合物 |
| JP2021085486A Active JP7207629B2 (ja) | 2013-06-28 | 2021-05-20 | Ｒａｆキナーゼおよび／またはＲａｆキナーゼの二量体阻害剤としての縮合三環式ウレア系化合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018135807A Active JP6707584B2 (ja) | 2013-06-28 | 2018-07-19 | Ｒａｆキナーゼおよび／またはＲａｆキナーゼの二量体阻害剤としての縮合三環式ウレア系化合物 |
| JP2020088185A Active JP6889311B2 (ja) | 2013-06-28 | 2020-05-20 | Ｒａｆキナーゼおよび／またはＲａｆキナーゼの二量体阻害剤としての縮合三環式ウレア系化合物 |
| JP2021085486A Active JP7207629B2 (ja) | 2013-06-28 | 2021-05-20 | Ｒａｆキナーゼおよび／またはＲａｆキナーゼの二量体阻害剤としての縮合三環式ウレア系化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9670203B2 (https=) |
| EP (1) | EP3013798B1 (https=) |
| JP (4) | JP6380861B2 (https=) |
| KR (1) | KR102272606B1 (https=) |
| CN (2) | CN109369671B (https=) |
| AU (1) | AU2014301816B2 (https=) |
| BR (1) | BR112015032539B1 (https=) |
| CA (1) | CA2916543C (https=) |
| DK (1) | DK3013798T3 (https=) |
| EA (1) | EA029412B1 (https=) |
| ES (1) | ES2686821T3 (https=) |
| IL (1) | IL242973A0 (https=) |
| MX (1) | MX362582B (https=) |
| NZ (1) | NZ716392A (https=) |
| PT (1) | PT3013798T (https=) |
| SG (1) | SG11201600147TA (https=) |
| WO (1) | WO2014206343A1 (https=) |
| ZA (1) | ZA201600513B (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| EA029412B1 (ru) * | 2013-06-28 | 2018-03-30 | Бейджин, Лтд. | Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf |
| EP3013797B1 (en) * | 2013-06-28 | 2018-01-03 | BeiGene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EP4006038A1 (en) | 2015-12-09 | 2022-06-01 | Cadent Therapeutics, Inc. | Thienopyrimidinone nmda receptor modulators and uses thereof |
| JP7071917B2 (ja) | 2015-12-09 | 2022-05-19 | カデント セラピューティクス，インコーポレーテッド | ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用 |
| US11274107B2 (en) | 2016-12-22 | 2022-03-15 | Cadent Therapeutics, Inc. | NMDA receptor modulators and uses thereof |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| AR115905A1 (es) | 2018-08-03 | 2021-03-10 | Cadent Therapeutics Inc | 5-(3-cloro-4-fluorofenil)-7-ciclopropil-3-(2-(3-fluoro-3-metilazetidin-1-il)-2-oxoetil)-3,7-dihidro-4h-pirrolo[2,3-d]pirimidin-4-ona como modulador de los receptores de nmda |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| CN111484490B (zh) * | 2019-01-25 | 2024-07-09 | 百济神州有限公司 | 适合大规模生产b-raf激酶二聚体抑制剂的方法 |
| TWI849043B (zh) * | 2019-01-25 | 2024-07-21 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
| CN111484489B (zh) * | 2019-01-25 | 2023-05-23 | 百济神州(北京)生物科技有限公司 | 无定形的b-raf激酶二聚体抑制剂 |
| CN111484488A (zh) * | 2019-01-25 | 2020-08-04 | 百济神州(北京)生物科技有限公司 | 一种b-raf激酶二聚体抑制剂的稳定结晶形式a |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US20240076272A1 (en) * | 2019-10-08 | 2024-03-07 | The Brigham And Women`S Hospital, Inc. | Activators of Heme Regulated Inhibitor Kinase (HRI) |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| RS65962B1 (sr) | 2020-05-08 | 2024-10-31 | Halia Therapeutics Inc | Inhibitori nek7 kinaze |
| US11345681B1 (en) | 2020-06-05 | 2022-05-31 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| JP2024504285A (ja) * | 2020-12-29 | 2024-01-31 | ティーエックスイノ バイオサイエンス インコーポレイテッド | エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼの阻害活性を有する新規のナフチリジノン誘導体及びこれらの用途 |
| WO2022216680A1 (en) | 2021-04-05 | 2022-10-13 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| WO2022226182A1 (en) | 2021-04-22 | 2022-10-27 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| WO2023240178A1 (en) * | 2022-06-08 | 2023-12-14 | Mapkure, Llc | Methods of treating cancer with a b-raf inhibitor |
| US20240158394A1 (en) | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| EP4593831A1 (en) * | 2022-09-26 | 2025-08-06 | Mapkure, LLC | Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer |
| JP2025534589A (ja) * | 2022-10-14 | 2025-10-17 | スプリングワークス、セラピューティクス、インコーポレイテッド | がんの治療に使用するための併用 |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
| TW202515875A (zh) | 2023-10-12 | 2025-04-16 | 瑞士商百濟神州瑞士有限責任公司 | 包含b-raf激酶二聚體抑制劑之固體形式、其製備方法及用途 |
| WO2025252204A1 (en) * | 2024-06-07 | 2025-12-11 | Beigene (Suzhou) Co., Ltd. | Amorphous solid dispersions of a braf inhibitor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100733D0 (sv) * | 2001-03-05 | 2001-03-05 | Medivir Ab | Non-nucleoside reverse transcriptase inhibitors |
| EP1534276B1 (en) * | 2002-09-05 | 2008-11-05 | Medivir AB | Non-nucleoside reverse transcriptase inhibitors |
| CN1925855B (zh) | 2003-12-19 | 2010-06-16 | 普莱希科公司 | 开发Ret调节剂的化合物和方法 |
| JP2008525355A (ja) | 2004-12-23 | 2008-07-17 | エフ．ホフマン−ラ ロシュ アーゲー | ベンズアミド誘導体、これらの製造及び医薬剤としての使用。 |
| WO2007067444A1 (en) * | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| EP2021327B1 (en) * | 2006-05-15 | 2012-04-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| KR101104666B1 (ko) | 2006-09-06 | 2012-01-13 | 에프. 호프만-라 로슈 아게 | 단백질 키나제 억제제로서의 헤테로아릴 유도체 |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| WO2009012283A1 (en) | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| GB0807609D0 (en) * | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| US20100197924A1 (en) | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| CN104958294A (zh) | 2010-01-27 | 2015-10-07 | 内尔维安诺医学科学有限公司 | 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物 |
| PL2797888T3 (pl) * | 2011-12-31 | 2016-12-30 | Połączone związki tricykliczne jako inhibitory kinazy raf | |
| EA029412B1 (ru) | 2013-06-28 | 2018-03-30 | Бейджин, Лтд. | Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf |
| EP3013797B1 (en) * | 2013-06-28 | 2018-01-03 | BeiGene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
-
2014
- 2014-06-27 EA EA201690098A patent/EA029412B1/ru not_active IP Right Cessation
- 2014-06-27 ES ES14818636.4T patent/ES2686821T3/es active Active
- 2014-06-27 BR BR112015032539-4A patent/BR112015032539B1/pt active IP Right Grant
- 2014-06-27 PT PT14818636T patent/PT3013798T/pt unknown
- 2014-06-27 US US14/901,634 patent/US9670203B2/en active Active
- 2014-06-27 CN CN201811172580.7A patent/CN109369671B/zh active Active
- 2014-06-27 DK DK14818636.4T patent/DK3013798T3/en active
- 2014-06-27 KR KR1020167001854A patent/KR102272606B1/ko active Active
- 2014-06-27 MX MX2016000143A patent/MX362582B/es active IP Right Grant
- 2014-06-27 CN CN201480037041.6A patent/CN105452223B/zh active Active
- 2014-06-27 NZ NZ716392A patent/NZ716392A/en unknown
- 2014-06-27 JP JP2016522232A patent/JP6380861B2/ja active Active
- 2014-06-27 EP EP14818636.4A patent/EP3013798B1/en active Active
- 2014-06-27 CA CA2916543A patent/CA2916543C/en active Active
- 2014-06-27 SG SG11201600147TA patent/SG11201600147TA/en unknown
- 2014-06-27 WO PCT/CN2014/080983 patent/WO2014206343A1/en not_active Ceased
- 2014-06-27 AU AU2014301816A patent/AU2014301816B2/en active Active
-
2015
- 2015-12-20 IL IL242973A patent/IL242973A0/en active IP Right Grant
-
2016
- 2016-01-22 ZA ZA2016/00513A patent/ZA201600513B/en unknown
-
2017
- 2017-04-28 US US15/581,728 patent/US9920055B2/en active Active
-
2018
- 2018-01-29 US US15/882,067 patent/US10208038B2/en active Active
- 2018-07-19 JP JP2018135807A patent/JP6707584B2/ja active Active
-
2019
- 2019-01-09 US US16/243,301 patent/US10562899B2/en active Active
-
2020
- 2020-05-20 JP JP2020088185A patent/JP6889311B2/ja active Active
-
2021
- 2021-05-20 JP JP2021085486A patent/JP7207629B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523269A5 (https=) | ||
| JP2017511311A5 (https=) | ||
| JP2017071634A5 (https=) | ||
| JP2016523270A5 (https=) | ||
| JP2017525753A5 (https=) | ||
| WO2014152389A8 (en) | Imaging agent for detection of diseased cells | |
| JP2017509586A5 (https=) | ||
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| JP2016522266A5 (https=) | ||
| WO2016080810A3 (ko) | 바이구아나이드 화합물 및 이의 용도 | |
| TR201906470T4 (tr) | İmmünomodülatörler. | |
| JP2019532084A5 (https=) | ||
| JP2016525135A5 (https=) | ||
| EP4275756A3 (en) | Bipyrazole derivatives as jak inhibitors | |
| JP2014193925A5 (https=) | ||
| JP2016525075A5 (https=) | ||
| JP2018516238A5 (https=) | ||
| JP2018519245A5 (https=) | ||
| JP2016538344A5 (https=) | ||
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| JP2016533366A5 (https=) | ||
| JP2016525076A5 (https=) | ||
| CY1119231T1 (el) | Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3 | |
| JP2017519027A5 (https=) | ||
| JP2016532647A5 (https=) |